{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:53:26Z","timestamp":1788872006772,"version":"build-2803163510"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T00:00:00Z","timestamp":1706054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Aim and background:<\/jats:bold> This study attempted to identify similarities and differences in adverse events (AEs) between human epidermal growth factor receptor 2 (HER2) inhibitors, especially those related to hemorrhagic events and nervous system disorders.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> This study summarized the types, frequencies, and system organ classes (SOCs) of AEs of HER2 inhibitors. The US Food and Drug Administration Adverse Event Reporting System (FAERS) data from January 2004 through March 2022 was collected and analyzed. Disproportionality analyses were conducted to detect AEs signals for every HER2 inhibitor. The chi-square test, Wilcoxon test, and descriptive analysis were used to compare the differences of AEs for specific SOCs or drugs.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> A total of 47,899 AE reports were obtained for eight HER2 inhibitors. Trastuzumab-related AEs were reported in the highest number and combination of regimens. In monotherapy, trastuzumab had the highest reported rate of cardiac disorders-related AEs (24.0%). However, small-molecule drugs exceeded other drugs in the reported rates of AEs related to gastrointestinal disorders, metabolism and nutrition disorders. The highest reported rates of respiratory disorders (47.3%) and hematologic disorders (22.4%) were associated with treatment with trastuzumab deruxtecan (T-DXd). Patients treated with trastuzumab emtansine (TDM-1) had the highest reported rate (7.28%) of hemorrhagic events, especially intracranial haemorrhage events. In addition, patients treated with TDM-1 with concomitant thrombocytopenia were likely to experience hemorrhagic events compared to other HER2 inhibitors (<jats:italic>p<\/jats:italic> &amp;lt; 0.001). The median time to onset of intracranial haemorrhage associated with trastuzumab (0.5\u00a0months) and TDM-1 (0.75\u00a0months) was short. However, there was no significant difference in median time to onset intracranial haemorrhage between patients in different age groups or with different outcomes. <jats:italic>Disproportionality analysis<\/jats:italic> results reveal that cerebral haemorrhage is a positive signal associated with T-DXd and TDM-1. In addition, tucatinib was the drug with the highest rate of reported nervous system disorders (31.38%). Memory impairment (83 cases) is a positive signal for tucatinib.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> The types and reporting rates of AEs associated with different HER2 inhibitors vary across multiple systems. In addition, hemorrhagic events concomitant with TDM-1 treatment and nervous system disorders concomitant with tucatinib treatment may be worthy of attention.<\/jats:p>","DOI":"10.3389\/fphar.2024.1288362","type":"journal-article","created":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T04:17:12Z","timestamp":1706069832000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["Comparing the difference of adverse events with HER2 inhibitors: a study of the FDA adverse event reporting system (FAERS)"],"prefix":"10.3389","volume":"15","author":[{"given":"Yiwen","family":"Bao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaju","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luting","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fujue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeming","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiliang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,1,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1097\/gco.0000000000000830","article-title":"New treatment strategies for human epidermal growth factor receptor 2-positive breast cancer in 2023","volume":"35","author":"Banys-Paluchowski","year":"2023","journal-title":"Curr. Opin. Obstet. Gynecol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"100188","DOI":"10.1016\/j.ctarc.2020.100188","article-title":"Safety and efficacy of T-DM1 in patients with advanced HER2-positive breast cancer the Royal Marsden experience","volume":"24","author":"Battisti","year":"2020","journal-title":"Cancer Treat. Res. Commun."},{"key":"B3","first-page":"4087","article-title":"Overexpression of HER-2\/neu is associated with poor survival in advanced epithelial ovarian cancer","volume":"50","author":"Berchuck","year":"1990","journal-title":"Cancer Res."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.21105\/joss.02017","article-title":"Ggalluvial: layered grammar for alluvial plots","volume":"5","author":"Brunson","year":"2020","journal-title":"J. Open Source Softw."},{"key":"B5","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa1903455","article-title":"Oral selinexor-dexamethasone for triple-class refractory multiple myeloma","volume":"381","author":"Chari","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1093\/cid\/ciac128","article-title":"Association between statin use and daptomycin-related musculoskeletal adverse events: a mixed approach combining a meta-analysis and a disproportionality analysis","volume":"75","author":"Chuma","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"B7","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1634\/theoncologist.9-6-606","article-title":"Prognostic and predictive factors in early-stage breast cancer","volume":"9","author":"Cianfrocca","year":"2004","journal-title":"Oncologist"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.1093\/bioinformatics\/btx364","article-title":"UpSetR: an R package for the visualization of intersecting sets and their properties","volume":"33","author":"Conway","year":"2017","journal-title":"Bioinformatics"},{"key":"B9","doi-asserted-by":"publisher","first-page":"100074","DOI":"10.1016\/j.esmoop.2021.100074","article-title":"The EMA review of trastuzumab emtansine (T-DM1) for the adjuvant treatment of adult patients with HER2-positive early breast cancer","volume":"6","author":"Delgado","year":"2021","journal-title":"ESMO Open"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1200\/jco.2001.19.4.1137","article-title":"Incidence, cost, and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia","volume":"19","author":"Elting","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.3390\/curroncol29040222","article-title":"Novel therapies for the treatment of HER2-positive advanced breast cancer: a Canadian perspective","volume":"29","author":"Ferrario","year":"2022","journal-title":"Curr. Oncol."},{"key":"B12","volume-title":"A 'ggplot2' implement of venn diagram","author":"ggVennDiagram","year":"2023"},{"key":"B13","doi-asserted-by":"publisher","first-page":"104185","DOI":"10.1016\/j.critrevonc.2023.104185","article-title":"Multidisciplinary management of HER2-positive breast cancer with brain metastases: an evidence-based pragmatic approach moving from pathophysiology to clinical data","volume":"192","author":"Giordano","year":"2023","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1200\/jco.22.00519","article-title":"Systemic therapy for advanced human epidermal growth factor receptor 2-positive breast cancer: ASCO guideline update","volume":"40","author":"Giordano","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1007\/s11864-021-00884-7","article-title":"HER2-Directed therapy in advanced gastric and gastroesophageal adenocarcinoma: triumphs and troubles","volume":"22","author":"Grieb","year":"2021","journal-title":"Curr. Treat. Options Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1093\/bioinformatics\/btw313","article-title":"Complex heatmaps reveal patterns and correlations in multidimensional genomic data","volume":"32","author":"Gu","year":"2016","journal-title":"Bioinformatics"},{"key":"B17","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s40478-020-00953-2","article-title":"Cerebrospinal fluid penetration of targeted therapeutics in pediatric brain tumor patients","volume":"8","author":"Guntner","year":"2020","journal-title":"Acta Neuropathol. Commun."},{"key":"B18","doi-asserted-by":"publisher","first-page":"221","DOI":"10.2174\/157340311799960636","article-title":"Cardiotoxicity of molecularly targeted agents","volume":"7","author":"Hedhli","year":"2011","journal-title":"Curr. Cardiol. Rev."},{"key":"B19","volume-title":"Ggpubr: 'ggplot2' based publication ready plots","author":"Kassambara","year":"2023"},{"key":"B20","doi-asserted-by":"publisher","first-page":"21709","DOI":"10.1002\/cam4.6730","article-title":"Evaluation of cardiotoxicity of anthracycline-containing chemotherapy regimens in patients with bone and soft tissue sarcomas: a study of the FDA adverse event reporting system joint single-center real-world experience","volume":"12","author":"Mo","year":"2023","journal-title":"Cancer Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1016\/j.ymthe.2023.03.019","article-title":"Clinical perspective: antibody-drug conjugates for the treatment of HER2-positive breast cancer","volume":"31","author":"Najminejad","year":"2023","journal-title":"Mol. Ther."},{"key":"B22","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41571-019-0268-3","article-title":"HER2-targeted therapies - a role beyond breast cancer","volume":"17","author":"Oh","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.21105\/joss.03167","article-title":"Visualizations with statistical details: the 'ggstatsplot' approach","volume":"6","author":"Patil","year":"2021","journal-title":"J. Open Source Softw."},{"key":"B24","doi-asserted-by":"publisher","first-page":"7597","DOI":"10.7314\/apjcp.2014.15.18.7597","article-title":"Evaluation of HER-2\/neu overexpression in gastric carcinoma using a tissue microarray","volume":"15","author":"Rakhshani","year":"2014","journal-title":"Asian Pac J. Cancer Prev."},{"key":"B25","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s40257-021-00645-0","article-title":"Skin toxicities with cyclin-dependent kinase 4\/6 inhibitors in breast cancer: signals from disproportionality analysis of the FDA adverse event reporting system","volume":"23","author":"Raschi","year":"2022","journal-title":"Am. J. Clin. Dermatol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41523-021-00265-1","article-title":"HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now","volume":"7","author":"Schlam","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1089066","DOI":"10.3389\/fphar.2022.1089066","article-title":"Clinical updates on tyrosine kinase inhibitors in HER2-positive breast cancer","volume":"13","author":"Singh","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1097\/01.cad.0000236313.50833.ee","article-title":"Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier","volume":"18","author":"Stemmler","year":"2007","journal-title":"Anticancer Drugs"},{"key":"B29","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/s1470-2045(19)30863-0","article-title":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study","volume":"21","author":"Swain","year":"2020","journal-title":"Lancet Oncol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"102378","DOI":"10.1016\/j.ctrv.2022.102378","article-title":"Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease\/pneumonitis-Focus on proactive monitoring, diagnosis, and management","volume":"106","author":"Swain","year":"2022","journal-title":"Cancer Treat. Rev."},{"key":"B31","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/s1470-2045(17)30111-0","article-title":"Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2\/3 study","volume":"18","author":"Thuss-Patience","year":"2017","journal-title":"Lancet Oncol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.thromres.2023.05.012","article-title":"Anticoagulation management and related outcomes in patients with cancer-associated thrombosis and thrombocytopenia: a systematic review and meta-analysis","volume":"227","author":"Wang","year":"2023","journal-title":"Thromb. Res."},{"key":"B33","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-24277-4","volume-title":"ggplot2: elegant graphics for data analysis","author":"Wickham","year":"2016"},{"key":"B34","doi-asserted-by":"publisher","first-page":"100561","DOI":"10.1016\/j.esmoop.2022.100561","article-title":"Final results of the global and Asia cohorts of KAMILLA, a phase IIIB safety trial of trastuzumab emtansine in patients with HER2-positive advanced breast cancer","volume":"7","author":"Wuerstlein","year":"2022","journal-title":"ESMO Open"},{"key":"B35","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1158\/1535-7163.Mct-15-0580","article-title":"Ado-trastuzumab emtansine targets hepatocytes via human epidermal growth factor receptor 2 to induce hepatotoxicity","volume":"15","author":"Yan","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"B36","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.breast.2010.11.002","article-title":"Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues","volume":"20","author":"Zambelli","year":"2011","journal-title":"Breast"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1288362\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T04:17:16Z","timestamp":1706069836000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1288362\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,24]]},"references-count":36,"alternative-id":["10.3389\/fphar.2024.1288362"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1288362","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,24]]},"article-number":"1288362"}}